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sures, or third-party opinion). The congruence of the
adherence measures was classiﬁed as high, medium or
low. This allowed a comparison of the congruence
between categories of adherence measures. RESULTS:
Eighty-four studies were identiﬁed that met the inclusion
criteria. The distribution of self-report measures were:
interview (n = 48), questionnaire (n = 22), diary (n = 14).
The non-self-report methods were: electronic measures (n
= 29), pill count/canister weight (n = 22), biological assays
(n = 17), claims (n = 10) and third-party opinion (n = 6).
There was substantial variation in the pattern of congru-
ence across the different types of self-report measures.
Interviews had the poorest congruence with other mea-
sures of adherence (only 15 of 48 comparisons found high
congruence). Diaries and Questionnaires were more likely
to exhibit high congruence with other measures (10 of 14
studies, and 12 of 22 studies, respectively). Only 5 of 
the 29 studies involving electronic measures reported 
high congruence with self-reports, although the other
non-self-report measures were often highly congruent
with self-report (32 of 53 studies). CONCLUSION: The 
congruence of self-report and other measures of medica-
tion adherence varies widely based upon the type of
measure.
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Terminology and conceptual causation models in patient
safety research arose separately in the ﬁelds of human
factors, epidemiology, engineering risk management, and
drug safety; they are confusing and conﬂict with one
another. Much of the terminology perpetuates undesir-
able concepts, such as implicit determination of causa-
tion, and poorly ﬁts an important arena, safety of medical
devices. OBJECTIVES: To review and propose terminol-
ogy and to propose a conceptual model for interpreting
research and designing interventions to reduce confusion
and enhance understanding and communication in this
area. METHODS: We systematically reviewed the termi-
nology used in scientiﬁc literature, discussed the mean-
ings, and made proposals. We also reviewed existing
models and proposed one that enhances the models that
are in the literature. RESULTS: We propose a set of terms
and deﬁnitions for “error,” “hazard,” “adverse event,”
“preventable adverse event,” “potential adverse event,”
and “risk.” The terms and their deﬁnitions are as neutral
as possible with respect to “blame issues” such as
“responsibility,” “negligence,” and “intentionality.” We
also proposed a model that builds on these ideas and on
Rothman’s “causal pie” concept. The concepts allow
explicit recognition of partial, rather than full, under-
standing of hazardous situations. CONCLUSIONS:
The proposed terms, deﬁnitions, and model could clarify
thought, research design and interpretation, the process
of designing and evaluating patient safety interventions,
and communication between interested parties, including
researchers, laypersons, healthcare providers, and risk
managers.
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OBJECTIVES: To assess the level of user acceptance for
an Internet-based methodology for collecting patient out-
comes data from an observational multi-site postmarket
study gathering data from community based ophthalmic
practices. METHODS: The study coordinator at each
participating site (N = 41) was issued an ID & Password
for logging onto the secure and conﬁdential site. Training
of the study coordinators on how to use the site and
patient conﬁdentiality considerations took about 30
minutes. Two sets of questions were being asked: Physi-
cian Questions (8 baseline, 4 followup) and Patient Ques-
tions (9 baseline, 18 followup). Patients were followed for
approximately six months. A small honorarium in return
for completing the study documents was paid. Both glau-
coma speciﬁc clinical & QOL data was collected and 
analyzed. RESULTS: Forty-one sites registered 360
patients for the study. Final follow-up data was entered
on 318 of the 360 registered patients (88%) using the
web-based case report forms. Eighty-seven percent
(36/41) responded to a user survey and all respondents
100% (36/36) felt the system was simple and east to use.
Several users were so enthusiastic they gave text quotes
of additional positive praise on the survey. Many indi-
cated they actually enjoyed participating. CONCLU-
SIONS: Internet-based post-market studies are a
promising methodology for the beneﬁt of both the study
sponsor and participating sites.
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OBJECTIVE: Evaluate the quality of retrospective study
design posters presented at the ISPOR Seventh Annual
Meeting using the criteria published by the ISPOR Task
Force on Retrospective Databases. METHODS: Of the
337 posters presented at the conference, we had access to
133 (39%) from on site collection or the ISPOR website.
These 133 posters were categorized into one of 5 cate-
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gories: Prospective, Retrospective, Modeling, Quality of
Life or Other. A total of 41 retrospective posters were
identiﬁed through this process, and all were evaluated
using a slightly modiﬁed ISPOR retrospective checklist (4
criteria were separated into components, yielding a total
of 14 points). This checklist helps evaluate the appropri-
ateness of the database, the study design, and the data
analysis procedures used. Posters were evaluated by three
reviewers to assess compliance with the criteria.
RESULTS: The median score was 7 points (out of 14 cri-
teria). The highest score was 11 points and the lowest
score was 5 points. More than three-fourths of the posters
did not conﬁrm the validity of their data (criterion 2),
inclusion/exclusion criteria (criterion 4b), sensitivity
analysis for controversial variables (criterion 5b), and 
the possibility of alternative explanations (criterion 10b).
More than half of the posters additionally failed to
acknowledge the study design limitations (criterion 3b),
describe the method and/or rationale for costing (crite-
rion 6), and control for confounding variables (criterion
7). CONCLUSION: Most of the posters in this conve-
nience sample ranked at the midpoint of the expanded
ISPOR checklist. Researchers should pay close attention
to the ISPOR checklist when preparing their poster pre-
sentations to assure consistently good research practices.
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OBJECTIVE: To evaluate whether the modeling posters
presented at the 2002 ISPOR Seventh Annual Interna-
tional Meeting met the standard of good research prac-
tice criteria established by British Medical Journal (BMJ)
and ISPOR. METHODS: Posters presented at the meeting
were collected onsite or from the ISPOR website. Of the
total 337 posters presented, 133 posters (39%) were eval-
uated. Of the 133 posters collected, 26 were classiﬁed 
as modeling. Nine (9) modeling posters were excluded
because they focused exclusively on the denominator or
numerator. The remaining 17 posters were evaluated in 3
major sections: a) study design (7 items for BMJ; 3 for
ISPOR); b) data validity (14 items for BMJ; 13 for
ISPOR); c) analysis and interpretation (14 items for BMJ;
23 for ISPOR). RESULTS: More than half of the posters
satisﬁed 75% or more of the ISPOR and BMJ criteria for
study design, and only 5 failed to satisfy at least 50% of
the study design criteria. Only six posters satisﬁed 50%
or more of the BMJ data validity criteria, and none of the
posters satisﬁed 50% or more of the ISPOR data validity
criteria. More than half of the posters satisﬁed 50% or
more of the BMJ and ISPOR criteria for analysis and
interpretation. Posters were slightly more likely to satisfy
the BMJ, rather than ISPOR criteria for data validity.
Overall, the 17 posters met 51% (18/35) of the BMJ cri-
teria and 46% (18/39) of the ISPOR criteria. CONCLU-
SIONS: The number of posters reviewed and the number
of evaluators limit this study. Reviewed posters revealed
satisfactory performance in the study design elements of
the ISPOR and BMJ guidelines, but could be improved 
in data validity and analysis. Generally, the posters per-
formed better when rated using the BMJ rather than the
ISPOR guideline.
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Pharmacoepidemiology is deﬁned as the application of
epidemiological reasoning methods and knowledge to the
study of the uses and effects (beneﬁcial and adverse) of
drugs in human populations. OBJECTIVES: The purpose
of this paper is to review the emerging role of pharma-
coepidemiology in outcomes research. METHODS: This
review has been based on a systematic literature search
using Medline (PubMed), including the abstracts of the
International Conference of Pharmacoepidemiolgy since
1990, and a review of core texts recommended by the
International Society for Pharmacoepidemiology (ISPE).
RESULTS: Three core functions were highlighted by
review of the literature. The major role was found to be
in the ﬁeld of pharmacovigilance and its function in phase
IV clinical trials or postmarketing surveillance. This was
reﬂected by the predominance of pharmacovigilance
abstracts accepted by the ISPE—90% (201/223) of
abstracts in 1990 and 72% (222/309) in 2001. Pharma-
covigilance, the process of identifying and responding to
drug safety issues during phase IV of drug development,
is a key requirement of many drug regulatory authorities,
including the FDA. Pharmacoepidemiology was also
found to play a role in drug utilisation review studies and
decision analytic modeling, although its use was found 
to be less substantial, constituting the balance of the
accepted abstracts. CONCLUSION: Although pharma-
coepidemiolgy has mainly been used in the ﬁeld of phar-
macovigilance, its use in decision analysis and drug
utilisation review was found to be on the increase.
PMD13
OPTIMIZING CLINICAL EFFECTIVENESS
THROUGH ACTUARIAL MODELING IN
HOSPITALS
Vogenberg FR1,Weinberg R1, Lichtig L1, Liebeskind D1,
Larrat EP2
1Aon Consulting, Wellesley, MA, USA; 2University of Rhode
Island College of Pharmacy, Kingston, RI, USA
OBJECTIVES: Current data support the use of low mol-
ecular weight heparin (LMWH) in lieu of unfractionated
